Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Lord CJ, Ashworth A.

Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7. Review.

PMID:
24202391
[PubMed - indexed for MEDLINE]
2.

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

Sandhu SK, Yap TA, de Bono JS.

Eur J Cancer. 2010 Jan;46(1):9-20. doi: 10.1016/j.ejca.2009.10.021. Epub . Review.

PMID:
19926276
[PubMed - indexed for MEDLINE]
3.

Targeted therapy for cancer using PARP inhibitors.

Lord CJ, Ashworth A.

Curr Opin Pharmacol. 2008 Aug;8(4):363-9. doi: 10.1016/j.coph.2008.06.016. Review.

PMID:
18644251
[PubMed - indexed for MEDLINE]
4.

A snapshot of chemoresistance to PARP inhibitors.

Chiarugi A.

Trends Pharmacol Sci. 2012 Jan;33(1):42-8. doi: 10.1016/j.tips.2011.10.001. Epub 2011 Nov 4.

PMID:
22055391
[PubMed - indexed for MEDLINE]
5.

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.

Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

PMID:
22983061
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A.

Nature. 2005 Apr 14;434(7035):917-21.

PMID:
15829967
[PubMed - indexed for MEDLINE]
Free Article
7.

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

Banerjee S, Kaye S.

Curr Oncol Rep. 2011 Dec;13(6):442-9. doi: 10.1007/s11912-011-0193-9. Review.

PMID:
21913063
[PubMed - indexed for MEDLINE]
8.

The clinical development of inhibitors of poly(ADP-ribose) polymerase.

Calvert H, Azzariti A.

Ann Oncol. 2011 Jan;22 Suppl 1:i53-9. doi: 10.1093/annonc/mdq667. Review.

PMID:
21285153
[PubMed - indexed for MEDLINE]
Free Article
9.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS.

Cell Cycle. 2011 Apr 15;10(8):1192-9. Epub 2011 Apr 15.

PMID:
21487248
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ.

BJOG. 2011 Mar;118(4):429-32. doi: 10.1111/j.1471-0528.2010.02838.x. Epub 2011 Jan 18. Review.

PMID:
21244617
[PubMed - indexed for MEDLINE]
11.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS.

N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.

PMID:
19553641
[PubMed - indexed for MEDLINE]
Free Article
12.

DNA repair deficiency as a therapeutic target in cancer.

Martin SA, Lord CJ, Ashworth A.

Curr Opin Genet Dev. 2008 Feb;18(1):80-6. doi: 10.1016/j.gde.2008.01.016. Epub 2008 Mar 14. Review.

PMID:
18343102
[PubMed - indexed for MEDLINE]
13.

Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Park SR, Chen A.

Hematol Oncol Clin North Am. 2012 Jun;26(3):649-70, ix. doi: 10.1016/j.hoc.2012.02.012. Review.

PMID:
22520984
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB.

J Clin Oncol. 2010 May 20;28(15):2512-9. doi: 10.1200/JCO.2009.26.9589. Epub 2010 Apr 20.

PMID:
20406929
[PubMed - indexed for MEDLINE]
Free Article
15.

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Clark CC, Weitzel JN, O'Connor TR.

Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.

PMID:
22778154
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.

Cipak L, Jantova S.

Neoplasma. 2010;57(5):401-5. Review.

PMID:
20568893
[PubMed - indexed for MEDLINE]
17.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

PMID:
23103855
[PubMed - indexed for MEDLINE]
18.

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

Ashworth A.

J Clin Oncol. 2008 Aug 1;26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. Epub 2008 Jun 30. Review.

PMID:
18591545
[PubMed - indexed for MEDLINE]
19.

Role of PARP inhibitors in cancer biology and therapy.

Davar D, Beumer JH, Hamieh L, Tawbi H.

Curr Med Chem. 2012;19(23):3907-21. Review.

PMID:
22788767
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].

Kluzek K, BiaƂkowska A, Koczorowska A, Zdzienicka MZ.

Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84. Review. Polish.

PMID:
22706123
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk